0.00Open1.33Pre Close0 Volume24 Open Interest125.00Strike Price0.00Turnover1641.20%IV15.07%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry1.33Time Value100Contract SizeAmericanOptions Type0.1797Delta0.0181Gamma82.55Leverage Ratio-80.4276Theta0.0000Rho14.83Eff Leverage0.0023Vega
Glaukos Stock Discussion
$Arcutis Biotherapeutics(ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co(MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co(MRK.US)$ : Approved ...
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US)$ $Vertex Pharmaceuticals(VRTX.US)$ $OptiNose(OPTN.US)$ $Arcutis Biotherapeutics(ARQT.US)$ $Calliditas Therapeutics(CALT.US)$ $bluebird bio(BLUE.US)$ $Glaukos(GKOS.US)$ $Ionis Pharmaceuticals(IONS.US)$ $Amgen(AMGN.US)$ $Merck & Co(MRK.US)$
im seeing some decent chart upside here
thoughts?
$SciSparc(SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US)$ gained 6% after We...
• $Canoo(GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics(ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel(WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences(GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
No comment yet